Complete coverage on


A class of injectable drugs used to treat autoimmune disorders such as rheumatoid arthritis doesn't raise the risk of serious infection when compared with more conventional treatments, according to a new analysis in the Journal of the American Medical Association.

Latest Stories Kim Kardashian Tries Psoriasis Remediesupdated: Mon Aug 01 2011 22:31:00

The reality star and bride-to-be Tweets about her battle with the skin condition Kim Kardashian Has Psoriasis - Not Ringwormupdated: Tue Jul 26 2011 02:55:00

"People don't understand the pressure on me to look perfect," the reality star says

Drugs for psoriasis, arthritis may lower diabetes riskupdated: Tue Jun 21 2011 17:42:00

Drugs that treat psoriasis and rheumatoid arthritis, or RA, by suppressing the immune system may also reduce the risk of developing diabetes, at least in people who already have one of these conditions, according to a new study in the Journal of the American Medical Association.

FDA: Psoriasis drug could cause deadly brain infectionupdated: Fri Feb 20 2009 12:39:00

The government is warning that taking the psoriasis drug Raptiva could result in serious brain infection and even death. LeAnn Rimes Recalls 'Scaly Girl' Kid Tauntsupdated: Mon Dec 22 2008 12:52:00

Others "didn't want to hang out with me or touch me," the singer says of her psoriasis LeAnn Rimes Discloses Her Struggle with Psoriasisupdated: Wed Sep 03 2008 15:13:00

The singer shares her experience in a new PSA to raise awareness of the disease

CNNMoney: Schering stock jumps on earnings winupdated: Tue Feb 12 2008 12:00:00

Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.

CNNMoney: Amgen earnings, sales beat forecastupdated: Thu Jan 24 2008 18:05:00

Biotech Amgen on Thursday reported an increase in earnings and a decrease in sales for the fourth quarter, beating Wall Street's forecast.

CNNMoney: Abbott's quarterly results top estimatesupdated: Wed Jan 23 2008 10:20:00

Abbott Laboratories, a maker of drugs and medical devices, reported on Wednesday a jump in sales and earnings that beat Wall Street's estimates.

CNNMoney: FDA approves Abbott drug for psoriasisupdated: Fri Jan 18 2008 17:00:00

The FDA approved Abbott's blockbuster drug Humira for yet another indication, psoriasis, the drugmaker said Friday.

No single remedy fixes psoriasisupdated: Sun Aug 12 2007 22:10:00

Psoriasis is an inflammatory skin condition that affects up to 5 million Americans. CNN learned more about psoriasis from Dr. Mathew Avram, director of the Massachusetts General Hospital Dermatology Laser and Cosmetics Center.

Health Minute: Psoriasisupdated: Sun Aug 12 2007 22:10:00

Health Minute: Psoriasis

CNNMoney: Amgen earnings meet forecastsupdated: Mon Apr 23 2007 16:11:00

The biotech Amgen reported first-quarter earnings Monday that matched expectations, though its revenue fell just short of forecasts.

CNNMoney: Congress said to want cheaper biotech drugsupdated: Sat Apr 07 2007 20:44:00

Senior Democrats and Republicans in Congress are hard at work on bills that would provide millions of Americans with cheaper copies of biotech drugs that can cost hundreds of thousands of dollars a year, a news report said Saturday.

CNNMoney: Abbott pitches Humira for psoriasisupdated: Mon Apr 02 2007 08:36:00

Abbott Laboratories is trying to get its top-selling blockbuster drug approved for yet another use, which could lead to further sales.

CNNMoney: Amgen reports surge in earnings, salesupdated: Thu Jan 25 2007 15:09:00

A surge in Amgen Inc's fourth-quarter earnings fell short of analyst projections, but the company's sales topped expectations.

CNNMoney: Abbott's Humira: More uses, more moneyupdated: Thu Aug 31 2006 13:26:00

Abbott Labs' fast-growing flagship drug Humira is grabbing market share and making money ... and now the company is trying to win the blessings of the FDA to make more.

CNNMoney: Amgen results don't cheer analystsupdated: Tue Apr 18 2006 17:40:00

Amgen Inc., the world's biggest biotech developer, beat earnings expectations for the first quarter Tuesday, but analysts were still skeptical about the company's performance.

This week in the medical journalsupdated: Fri Oct 21 2005 10:23:00

Drug safety made headlines in the major medical journals this week when noted Cleveland Clinic cardiologists came up with a disturbing analysis about a new diabetes drug that is just a hair away from approval by the Food and Drug Administration.

CNNMoney: Could Celebrex survive a black box?updated: Tue May 03 2005 10:48:00

The black box label is the most potent warning in the Food and Drug Administration's arsenal, but it is not necessarily a death knell for drug sales, analysts say.

Firm warns doctors of arthritis drug riskupdated: Fri Oct 08 2004 10:53:00

Johnson & Johnson says its rheumatoid arthritis drug Remicade may put patients at higher risk for lymphoma, and the company is sending out warning letters to physicians.

Fortune: Elite Factoriesupdated: Mon Sep 06 2004 00:01:00

A common thread connects this year's standouts: They all responded to crisis by radically changing the way they make things. Autoliv reprocessed its factory to fend off stiff competition in airbags...

Fortune: Growing Against The Grain Amgen CEO Kevin Sharer stands accused of remaking the world's biggest biotech company in the image of updated: Mon May 03 2004 00:01:00

The Empire State ballroom at the Grand Hyatt Hotel in midtown Manhattan typically serves as the setting for the kind of stuffy, state-of-a-business luncheons that are more snooze inducing than buzz...

Money Magazine: Blue Chip WINNERS & LOSERS Bigger may be better--the 50 largest stocks account for more than half of updated: Sat Jun 01 2002 00:01:00

The economy seems to be chugging back onto the right track, and Wall Street wisdom (no jokes, please) has stocks rising this year after two consecutive annual declines. But before you jump for joy,...

Fortune: Biotech's New Colossus Move over, Big Pharma. Amgen boasts better growth.updated: Mon Apr 15 2002 00:01:00

For years Amgen has seemed biotechnology's best answer to the likes of Merck--a sector leader with so much heft and momentum that you'd recommend its stock to your mom. But now making that analogy ...

Money Magazine: Biotech Grows Up With real profits and a wave of new drugs, it's a sector few investors can ignore anymore.updated: Fri Mar 01 2002 00:01:00

The first wave in biotechnology investing arrived back in the late 1980s, when revolutionary new medicines created by pioneers like Amgen alerted investors to the fledgling sector's potential. The ...

Fortune: Finding The Bulls In Biotech The sector is blazing, the science ever more titillating. But with share prices up 214% in three yeupdated: Mon Feb 04 2002 00:01:00

On Dec. 17, Amgen, the flagship company of the biotechnology world, closed the biggest merger in the sector's history. It agreed to pay $16 billion to buy rival Immunex, primarily for the right to ...

Fortune: U.S. Faces Protein Deficiencyupdated: Mon May 28 2001 00:01:00

Patients who want the rheumatoid arthritis-fighting drug Enbrel have to show a special card to their pharmacist, who then verifies that the patient is enrolled in the Enbrel program before dispensi...

Money Magazine: Profile: Examine With Care Caution and research are the hallmarks of this doctor's style.updated: Thu Apr 01 1999 00:01:00

Like any good family practitioner, Dr. Reginald Parker believes in protecting against loss. So he begins his financial exams with some basic questions: What stocks do the mutual funds own? What ind...

Fortune: THE TICKERupdated: Mon Oct 27 1997 00:01:00



In a dimly lit operating room at the Thompson Cancer Survival Center in Knoxville, Tennessee, a surgeon uses an endoscope to guide an optical fiber down the throat of a patient afflicted with cance...

We recommend